- Home
- CUE vs OPTN Comparison
CUE vs OPTN Comparison
Compare CUE & OPTN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CUE
- OPTN
- Stock Information
- Founded
- CUE 2014
- OPTN 2010
- Country
- CUE United States
- OPTN United States
- Employees
- CUE N/A
- OPTN N/A
- Industry
- CUE Biotechnology: Pharmaceutical Preparations
- OPTN Biotechnology: Pharmaceutical Preparations
- Sector
- CUE Health Care
- OPTN Health Care
- Exchange
- CUE Nasdaq
- OPTN Nasdaq
- Market Cap
- CUE 77.3M
- OPTN 78.4M
- IPO Year
- CUE 2018
- OPTN 2017
- Fundamental
- Price
- CUE $1.07
- OPTN $0.46
- Analyst Decision
- CUE Strong Buy
- OPTN Strong Buy
- Analyst Count
- CUE 5
- OPTN 3
- Target Price
- CUE $5.00
- OPTN $3.00
- AVG Volume (30 Days)
- CUE 378.2K
- OPTN 1.2M
- Earning Date
- CUE 11-14-2024
- OPTN 11-12-2024
- Dividend Yield
- CUE N/A
- OPTN N/A
- EPS Growth
- CUE N/A
- OPTN N/A
- EPS
- CUE N/A
- OPTN N/A
- Revenue
- CUE $9,532,000.00
- OPTN $75,672,000.00
- Revenue This Year
- CUE $105.39
- OPTN $13.42
- Revenue Next Year
- CUE N/A
- OPTN $52.99
- P/E Ratio
- CUE N/A
- OPTN N/A
- Revenue Growth
- CUE 149.53
- OPTN 5.13
- 52 Week Low
- CUE $0.45
- OPTN $0.32
- 52 Week High
- CUE $3.20
- OPTN $2.10
- Technical
- Relative Strength Index (RSI)
- CUE 45.52
- OPTN 39.55
- Support Level
- CUE $0.92
- OPTN $0.42
- Resistance Level
- CUE $1.09
- OPTN $0.57
- Average True Range (ATR)
- CUE 0.11
- OPTN 0.05
- MACD
- CUE 0.00
- OPTN 0.00
- Stochastic Oscillator
- CUE 45.71
- OPTN 26.39
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune disease with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103 and others.
About OPTN OptiNose Inc.
OptiNose Inc is a specialty pharmaceutical company focuses on the development and commercialization of products for patients treated by ear, nose, and throat (ENT), and allergy specialists. Its first commercial product, XHANCE (fluticasone propionate) nasal spray, 93 microgram (mcg), is a therapeutic utilizing the proprietary Exhalation Delivery System (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps.